



PATENT
Attorney Docket No. FJN-077

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Tani et al.

SERIAL NO.: 09/423,905 GROUP NO.: 1645

FILING DATE: March 19, 1999 EXAMINER: P. Duffy, Ph.D.

TITLE: Therapeutic Agent for Preventing and/or Treating Sepsis

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filings date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
 - the requisite Statement is below, **OR**
 - the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

10/27/2004 MBLANCO 00000025 09423905
180.00 0P
02 FC:1806


(3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee**, AND

the requisite Statement is below, AND

the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Brian Fairchild, Ph.D.
Attorney for Applicant(s)
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

Date: October 25, 2004
Reg. No. 48,645

Tel. No.: (617) 248-7697
Fax No.: (617) 248-7100

3134975_1



SHEET 1 OF 1

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: FJN-077 APPLICANT(S): Tani et al. SERIAL NO.: 09/423,905 FILING DATE: March 19, 1999 GROUP: 1645					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	C1	EP 99 90 9244 European Search Report (2 pgs.)							
	C2	Penner, M.D., John A.; "Disseminated Intravascular Coagulation in Patients with Multiple Organ Failure of Non-Septic Origin," <u>Seminars in Thrombosis and Hemostasis</u> , 24(1): 45-52 (1998).							
	C3	Hernandez <i>et al.</i> ; "Characterization of the Effects of Human Placental HGF on Rat Hepatocytes," <u>Journal of Cellular Physiology</u> , 150: 116-121 (1992).							
	C4	Yajima <i>et al.</i> ; "Non-septic endotoxemia in cirrhotic patients," <u>Gastroenterologia Japonica</u> , 24(3): 262-269 (1989).							
	C5	Zeng <i>et al.</i> ; "Prevention of endotoxic shock in rats with hepatic stimulating substance," <u>Chinese Journal of Internal Medicine</u> , 35(2): 99-102 (1996). [Abstract only]							
EXAMINER					DATE CONSIDERED				

3134927_1